NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Latin American Cooperative Oncology Group
Conditions: Anal Squamous Cell Carcinoma, HIV Infections
Countries: Argentina, Brazil, Mexico, Peru, Uruguay
Due to the scarcity of data on prognostic and predictive influence on CCA, epidemiological studies evaluating these factors need to be developed in patients with CCA. Therefore, the investigators want to evaluate the profile of patients in the real world and from various parts of the world, describing prognostic factors such as CD4 dosage, time of HIV infection, evaluation of viral load, diagnosis of AIDS, geographic region of diagnosis and treatment, clinical staging, medications concomitant with QRT (risk of drug interactions), comorbidities (possible impact on dose-intensity), use of HAART, time of use of HAART, radiotherapy modality (conventional 3D vs Modulated Beam Intensity \[IMRT\], response to Nigro vs CTII regimens, as well as comparing clinical outcomes with patients without HIV infection.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Patients 18 years of age or older * Confirmed histological diagnosis of anal canal squamous cell carcinoma. Basaloid subtype is accepted * Have underundered serological test for HIV infection * Any clinical stage Exclusion Criteria: * Lack of data on treatments and clinical outcomes
- Buenos Aires, Buenos Aires, Argentina
- Rio de Janeiro, Rio de Janeiro, Brazil
- Natal, Rio Grande do Norte, Brazil
- Natal, Rio Grande do Norte, Brazil
- Florianópolis, Santa Catarina, Brazil
- Barretos, São Paulo, Brazil
- São Paulo, São Paulo, Brazil
- Mexico City, Mexico City, Mexico
- Lima, Peru, Peru
- Lima, Peru, Peru
- Montevideo, Uruguai, Uruguay